AMPLIFY
Apixaban for the Initial Management of Pulmonary Embolism and Deep-Vein Thrombosis
Paziente / Popolazione Intervento / Esposizione Confronto Esito
In 5,395 patients with acute venous thromboembolism, apixaban was non-inferior to conventional heparin–warfarin therapy for recurrent VTE, with far less major bleeding.
N
5395
Disegno
Double-blind, double-dummy RCT
Esito
Recurrent VTE or VTE-related death
Rilevanza
1
Risultato2.3 % vs 2.7 % (non-inferior); major bleeding 0.6 % vs 1.8 % (RR 0.31).
Agnelli G, et al. N Engl J Med. 2013;369(9):799-808. 10.1056/NEJMoa1302507
Discussione e critica
A single-drug oral regimen with no heparin lead-in. The 69 % reduction in major bleeding is the headline; AMPLIFY-EXT extended the low-dose secondary-prevention story.